You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 6,548,527

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,548,527

Title:	Treatments for immune-mediated ear disorders
Abstract:	Disclosed herein are methods for treating immune-mediated ear disorders, such as IMCVDs, or their symptoms, involving administration of a therapeutically-effective amount of a TNF antagonist, such as etanercept or infliximab, or a therapeutically-effective amount of a pyrimidine synthesis inhibitor, such as leflunomide.
Inventor(s):	Rahman; Mahboob U. (Sharon, MA), Poe; Dennis S. (Chestnut Hill, MA), Choi; Hyon K. (Lexington, MA)
Assignee:	The General Hospital Corporation (Boston, MA)
Application Number:	09/818,411
Patent Claims:	1. A method of treating a mammal with an immune-mediated ear disorder, said method comprising administering to said mammal a therapeutically-effective amount of a TNF antagonist. 2. The method of claim 1, wherein said mammal is a human. 3. The method of claim 1, wherein said immune-mediated ear disorder is an immune-mediated cochlear or vestibular disorder (IMCVD). 4. The method of claim 1, wherein said immune-mediated ear disorder involves a hearing impairment. 5. The method of claim 1, wherein said immune-mediated ear disorder is autoimmune-mediated. 6. The method of claim 1, wherein said immune-mediated ear disorder affects the inner ear. 7. The method of claim 1, wherein said TNF antagonist is a TNF-.alpha. antagonist. 8. The method of claim 1, wherein said TNF antagonist is a TNF fusion protein. 9. The method of claim 1, wherein said TNF antagonist is etanercept. 10. The method of claim 1, wherein said TNF antagonist is infliximab. 11. The method of claim 1, wherein said method further comprises administering a pyrimidine synthesis inhibitor, a steroid, an anti-inflammatory compound, a cytotoxic compound, an anti-neoplastic metabolite, or a secondary anti-rheumatic agent to said mammal. 12. The method of claim 11, wherein said pyrimidine synthesis inhibitor is leflunomide. 13. The method of claim 11, wherein said secondary anti-rheumatic agent is methotrexate.

Details for Patent 6,548,527

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2020-03-27
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2020-03-27
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2020-03-27
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2020-03-27
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2020-03-27
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2020-03-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.